Comparative Study of Development and Analysis of Antibiotic Tetracycline HCL Tablet with Marketed Preparations

Tetracyclines are among the earliest broad-spectrum antibiotics that are well-tolerated and easy to administer. They are effective against various diseases, including plague, cholera, typhoid, syphilis, Legionnaire’s disease, and anthrax. Additionally, some tetracyclines can be utilized in the treatment of malaria, Lyme disease, tuberculosis, Rocky Mountain spotted fever, and leprosy. Historical evidence suggests that humans first encountered these chemical compounds involuntarily in ancient times, as indicated by the analysis of bone samples that are over 1500 years old.
Following World War II, these antibiotics were “rediscovered” at Lederle Laboratories and Pfizer due to a vigorous search for new antibiotic options. Their bacteriostatic properties arise from the inhibition of protein biosynthesis. Since the structural elucidation by Robert Woodward, Lloyd Hillyard Conover, and others in the 1950s, tetracyclines have become prime targets for the synthesis of natural products. The casual and indiscriminate use of tetracyclines in the initial decades after their introduction, not only in humans but also for veterinary applications and as growth promoters in meat production, quickly led to the development of resistance.
A significant achievement in this field was accomplished by Andrew Myers in 2005 with the convergent total synthesis of (−)-doxycycline, along with various azatetracyclines and pentacyclines, which has motivated chemists in the pharmaceutical industry to seek out novel and highly effective tetracyclines in recent years.